Novartis has been granted a patent for compositions and methods to regulate T cell specificity and activity. The invention includes a unique chimeric antigen receptor (CAR) called “KIR-CAR” incorporating components of natural killer (NK) cell receptors. The patent claim describes a purified inhibitory KIR-CAR with specific structural elements. GlobalData’s report on Novartis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Novartis, Cancer treatment biomarkers was a key innovation area identified from patents. Novartis's grant share as of February 2024 was 69%. Grant share is based on the ratio of number of grants to total number of patents.
Chimeric antigen receptor for t cell specificity regulation
A recently granted patent (Publication Number: US11919946B2) discloses a purified inhibitory killer cell immunoglobulin-like receptor chimeric antigen receptor (inhKIR-CAR) that includes an extra-cellular antigen binding domain from an antibody molecule or a non-antibody scaffold, a transmembrane domain, and a cytoplasmic domain. The inhKIR-CAR does not contain a KIR D domain in the non-antibody scaffold. Additionally, the patent claims variations of the inhKIR-CAR, such as those with a KIR-cytoplasmic domain, an extracellular hinge domain, or a cytoplasmic domain from an inhibitory receptor other than a KIR.
Furthermore, the patent describes specific features of the inhKIR-CAR, including the use of antigen binding domains like scFv, single heavy chain variable domain (VH) domain, nanobody, immunoglobulin single domain antibody (sdAb), or single light chain variable domain (VL). The antigen binding domain can target antigens like desmoglein1/3 (DSG1/3), ephrin receptor, or a claudin. The cytoplasmic domain may contain an immunoreceptor tyrosine-based inhibitory motif (ITIM) and can be derived from inhibitory receptors like PD-1, CTLA4, CD85, Siglec, CD300, and/or SLAM gene families. Notably, the inhKIR-CAR is designed to bind antigens not only present on cancer cells but also those more highly expressed on non-cancer cells compared to cancer cells of the same type.
To know more about GlobalData’s detailed insights on Novartis, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
